Učitavanje...
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach in the reduction of residual risk of cardiovascular disease. The progr...
Spremljeno u:
| Izdano u: | BMC Med |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4601145/ https://ncbi.nlm.nih.gov/pubmed/26456772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0503-4 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|